임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
53건 표시
- 2상모집 중· Generalized Myasthenia GravisA Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
리드: 암젠
- 2상모집 예정· Immunoglobulin G4-related DiseaseStudy to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
리드: 암젠
- 2상모집 예정· Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
협력: 암젠
- 2상모집 중· Thyroid Eye DiseaseAn Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
리드: 암젠
- 2상모집 중· Extensive Stage Lung Small Cell CancerA Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
협력: 암젠
- 2상모집 중· Extensive Stage Lung Small Cell CarcinomaTarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
협력: 암젠
- 2상모집 중· Overweight or Obesity and Elevated Liver FatA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
리드: 암젠
- 2상모집 중단 (진행 중)· B-cell Acute Lymphoblastic LeukemiaA Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
협력: 암젠
- 2상모집 중· Advanced Solid TumorsA Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
리드: 암젠
- 2상모집 중· Advanced Neuroendocrine Carcinomas of The Digestive SystemRefractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
협력: 암젠
- 2상모집 중· Systemic Lupus ErythematosusA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
리드: 암젠
- 2상모집 중· Metastatic/Locally Advanced Small-Cell Lung CancerStudy Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
협력: 암젠
- 2상모집 예정· Extrapulmonary Small Cell Carcinoma and Neuroendocrine CarcinomaTarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)
협력: 암젠
- 2상모집 중· DLL3-expressing TumorsTarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
협력: 암젠
- 2상모집 중단 (진행 중)· Metastatic Gastro-esophageal AdenocarcinomaBemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
협력: 암젠
- 2상모집 중단 (진행 중)· Soft Tissue SarcomaNeoadjuvant Intralesional Injection of Talimogene Laherparepvec
협력: 암젠
- 2상모집 중단 (진행 중)· Small Cell Lung Cancer (SCLC)A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
리드: 암젠
- 2상모집 중· Acute Lymphoblastic LeukemiaTherapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
협력: 암젠, 화이자
- 2상모집 중단 (진행 중)· MTAP-deleted NSCLCA Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
리드: 암젠
- 2상모집 중단 (진행 중)· Type 2 Diabetes Mellitus (T2DM)A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
리드: 암젠
- 2상모집 중단 (진행 중)· Extensive Stage Small Cell Lung CancerStudy Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
리드: 암젠
- 2상모집 중단 (진행 중)· B Precursor Acute Lymphoblastic LeukemiaStudy of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
리드: 암젠
- 2상모집 중· Neuromyelitis Optica Spectrum DisorderStudy of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
리드: 암젠
- 2상모집 중· Multiple MyelomaStudy of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
협력: 암젠, GSK
- 2상모집 중단 (진행 중)· Relapsed/Refractory Small Cell Lung CancerA Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
리드: 암젠
- 2상모집 중단 (진행 중)· Waldenstrom MacroglobulinemiaEfficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
협력: 암젠
- 2상모집 중단 (진행 중)· Premenopausal Idiopathic OsteoporosisRomosozumab/Denosumab Study for Premenopausal IOP
협력: 암젠
- 2상모집 중· B-cell Acute Lymphoblastic LeukemiaBlinatumomab After TCR Alpha Beta/CD19 Depleted HCT
협력: 암젠
- 2상모집 중단 (진행 중)· Colorectal CancerPAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
협력: 암젠
- 2상모집 중단 (진행 중)· Multiple MyelomaDaratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
협력: 암젠, 얀센(J&J)
- 2상모집 중단 (진행 중)· Acute Lymphoblastic LeukemiaBlinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
협력: 암젠
- 2상모집 중단 (진행 중)· Multiple MyelomaA Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
협력: 암젠
- 2상모집 중단 (진행 중)· Multiple MyelomaStudy of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
협력: 암젠
- 2상모집 예정· Treatment Related CancerOptimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
협력: 암젠
- 2상초청 등록· Multiple MyelomaA Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
협력: 암젠
- 2상모집 중단 (진행 중)· Plasma Cell MyelomaCarfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
협력: 암젠
- 2상모집 중단 (진행 중)· HER2-positive Breast CancerImpact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer
협력: 암젠
- 2상모집 중단 (진행 중)· Smoldering Multiple MyelomaAggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
협력: 암젠
- 2상모집 중· Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
협력: 암젠, 다케다
- 2상모집 중단 (진행 중)· SarcomaA Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
협력: 암젠, 머크(MSD)
- 2상모집 중단 (진행 중)· Breast CarcinomaCarboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
협력: 암젠
- 2상모집 중· CancerThe Drug Rediscovery Protocol (DRUP Trial)
협력: 암젠, 아스트라제네카, BMS, GSK, 일라이 릴리, 머크(MSD), 노바티스, 화이자
- 2상모집 중단 (진행 중)· Multiple MyelomaCarfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma
협력: 암젠
- 2상모집 중단 (진행 중)· Smoldering Multiple MyelomaCarfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
협력: 암젠
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.